| Identification | Back Directory | [Name]
H-GLY-TYR-GLY-SER-SER-SER-ARG-ARG-ALA-PRO-GLN-THR-OH | [CAS]
82177-09-1 | [Synonyms]
IGF-I (30-41)
IGF-I C-PEPTIDE
IGF-1 C-PEPTIDE
IGF-I FRAG 30-41
IGF-I, HUMAN (30-41)
IGF-IC-PEPTIDE HUMAN
IGF-I (30-41)
IGF-I C-Peptide
INSULIN-LIKE GROWTH FACTOR I (30-41)
INSULIN-LIKE GROWTH FACTOR-I, HUMAN (30-41)
GLY-TYR-GLY-SER-SER-SER-ARG-ARG-ALA-PRO-GLN-THR
INSULIN-LIKE GROWTH FACTOR I, FRAGMENT 30-41 HUMAN
IGF-I (30-41)|Insulin-Like Growth Factor I (30-41)
H-GLY-TYR-GLY-SER-SER-SER-ARG-ARG-ALA-PRO-GLN-THR-OH
Glycyl-L-tyrosylglycyl-L-seryl-L-seryl-L-seryl-L-arginyl-L-arginyl-L-alanyl-L-prolyl-L-glutaminyl-L-threonine
L-Threonine, glycyl-L-tyrosylglycyl-L-seryl-L-seryl-L-seryl-L-arginyl-L-arginyl-L-alanyl-L-prolyl-L-glutaminyl- | [Molecular Formula]
C51H83N19O19 | [MDL Number]
MFCD00076549 | [MOL File]
82177-09-1.mol | [Molecular Weight]
1266.32 |
| Hazard Information | Back Directory | [Uses]
IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions)[1]. | [References]
[1] Puche JE, et al. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med. 2012 Nov 14;10:224. DOI:10.1186/1479-5876-10-224 |
|
|